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Significance of this study
What is already known about this subject?
 ► Inflammatory processes play a role in chronic kidney 
disease in type 2 diabetes.
 ► The variation in glycan sugar residues attached to 
the conserved glycosylation sites of the immuno-
globulin G (IgG) Fc part influences IgG effector func-
tion, modulating the immune response from either 
pro- inflammatory to an anti- inflammatory response 
or vice versa.
 ► The link between IgG glycosylation and renal func-
tion in type 2 diabetes has never been investigated.
What are the new findings?
 ► We found pro- inflammatory IgG N- glycosylation 
patterns associated with a faster decline of kidney 
function estimated glomerular filtration rate, but not 
albumin- to- creatinine ratio, possibly representing 
renal macroangiopathy.
How might these results change the focus of 
research or clinical practice?
 ► Our findings suggest the involvement of the immune 
system in the pathophysiology of diabetic nephrop-
athy in type 2 diabetes, representing a novel target 
for future biomarker and therapeutics developments.
AbStrAct
Introduction Inflammatory processes are thought to 
be involved in kidney function decline in individuals 
with type 2 diabetes. Glycosylation of immunoglobulin G 
(IgG) is an important post- translation process affecting 
the inflammatory potential of IgG. We investigated the 
prospective relationship between IgG N- glycosylation 
patterns and kidney function in type 2 diabetes.
Research design and methods In the DiaGene study, 
an all- lines- of- care case–control study (n=1886) with 
mean prospective follow- up of 7.0 years, the association 
between 58 IgG N- glycan profiles and estimated 
glomerular filtration rate (eGFR) and albumin- to- creatinine 
ratio (ACR) per year and during total follow- up was 
analyzed. Models were adjusted for clinical variables and 
multiple comparisons.
Results Eleven traits were significantly associated with 
eGFR change per year. Bisecting GlcNAc in fucosylated and 
fucosylated disialylated structures and monosialylation of 
fucosylated digalactosylated structures were associated 
with a faster decrease of eGFR. Fucosylation of neutral and 
monogalactosylated structures was associated with less 
eGFR decline per year. No significant associations between 
IgG glycans and ACR were found.
Conclusions In type 2 diabetes, we found IgG N- 
glycosylation patterns associated with a faster decline 
of kidney function, reflecting a pro- inflammatory state of 
IgG. eGFR, but not ACR, was associated with IgG glycans, 
which suggests these associations may represent renal 
macroangiopathy rather than microvascular disease.
InTRoduCTIon
Chronic kidney disease (CKD) is one of 
the most common complications in type 2 
diabetes mellitus, despite extensive preven-
tive efforts. Apart from known risk factors, 
a large residual risk remains for developing 
CKD,1 2 which may be partly explained by 
processes such as inflammation. Biomarkers 
that provide information, in addition to 
known risk factors, can aid in better predic-
tion and tailored treatment to prevent and 
delay kidney function decline.3 4
A growing body of literature recognizes the 
association between type 2 diabetes and the 
N- linked glycosylation of proteins.5 N- Linked 
glycosylation is a co- translational and 
post- translational modification of proteins, 
influencing their function.6 7 N- Glycans affect 
the stability, activity and targeting of proteins, 
as well as cell–cell and host–pathogen inter-
action.6 7 These complex oligosaccharides 
are assembled by the coordinated action 
of a range of glycosyltransferases and glyco-
sidase enzymes, and are attached to the 
nitrogen (N) atom of asparagine side chains 
of proteins within a specific sequon.6 N- Gly-
cosylation patterns of the IgG N- glycome 
and total plasma N- glycome have been asso-
ciated with estimated glomerular filtration 
rate (eGFR) in non- diabetic individuals and 
those with type 1 diabetes.8 9 Furthermore, a 
cross- sectional study showed that character-
istic patterns of the total plasma N- glycome 
are associated with renal function in type 2 
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Figure 1 Functional implications and inflammatory associations of IgG glycosylation. Dark- green spots on IgG molecule are 
conserved glycosylation sites Asn297 to which biantennary glycans are attached.
diabetes.10 However, the link between the immunoglob-
ulin G (IgG) N- glycome and renal function in type 2 
diabetes patients has never been investigated. Immuno-
globulin G (IgG) is the most abundant antibody in the 
human body, involved in infectious and inflammatory 
processes through several mechanisms: antigen neutral-
ization, promotion of phagocytosis, microbial killing via 
opsonization and macrophage activation, complement 
activation and induction of ADCC (antibody- dependent 
cellular cytotoxicity).11 IgG consist of a fragment antigen 
binding (Fab) domain and fragment crystallizable 
(Fc) domain, which interacts with Fc gamma receptors 
(FcyR). Single biantennary glycans are attached to each 
heavy chain on the Fc part asparagine-297 (Asn297). 
They are essential for binding to the FcyRs. The receptor 
interaction is lost if no glycans are attached. The varia-
tion in glycan sugar residues attached influences IgG 
effector function, modulating the immune response 
from either pro- inflammatory to an anti- inflammatory 
response or vice versa. The variations consist of the addi-
tion of bisecting N- acetylglucosamine (GlcNac), fucose to 
core, as well as galactose and sialic acid to the arms of the 
biantennary glycan. Bisecting GlcNac and afucosylated 
N- glycans have a pro- inflammatory effect, while the addi-
tion of galactose and sialic acid has an anti- inflammatory 
effect on IgG (figure 1).12 IgG glycosylation patterns 
are highly variable between individuals, but show good 
temporal stability in a single healthy individual.13 Yet, 
IgG patterns are known to change in a single individual 
because of alterations in a person’s health status.13–15 IgG 
glycosylation contains a genetic, heritable component, 
as well an environmental component. Because of these 
features, glycosylation is considered an interface between 
genetic background and environment.14 1612 17 18 Because 
type 2 diabetes and chronic kidney disease are multifac-
torial diseases displaying features of chronic inflamma-
tion, IgG N- glycosylation is promising as a biomarker, but 
also from a pathophysiological perspective.19
We hypothesized that specific IgG- glycan profiles 
prospectively associate with kidney function in type 2 
diabetes, and could be a potential biomarker in the future 
We, therefore, investigated the prospective relationship 
between IgG N- glycosylation and the course of kidney 
function during follow- up in type 2 diabetes individuals.
3BMJ Open Diab Res Care 2020;8:e001026. doi:10.1136/bmjdrc-2019-001026
Pathophysiology/Complications
ReseaRCH desIgn and meTHods
study design
Data were derived from the DiaGene study, and the study 
characteristics have previously been described in more 
detail.20 Briefly, the DiaGene study is a large multicenter 
prospective cohort study with 1886 patients with type 2 
diabetes with prospective follow- up on kidney function 
(mean follow- up time=7.0 years). Data were collected 
from two hospitals in and around the city of Eindhoven, 
the Netherlands. In addition, the local primary care diag-
nostic center participated in the study. All participants 
provided informed written consent.
definitions
Type 2 diabetes was defined as fasting plasma glucose 
≥7.0 mmol/L and/or a non- fasting plasma glucose level 
≥11.1 mmol/L measured at least at two separate time 
points, treatment with oral glucose- lowering medica-
tion or insulin, and/or the diagnosis of type 2 diabetes 
as registered by a medical specialist. Microalbuminuria 
was defined as urinary albumin- to- creatinine ratio (ACR) 
≥2.5 for men or ≥3.5 for women. Macroalbuminuria was 
defined as ACR ≥12.5 for men or ≥17.5 for women. Around 
the moment of inclusion, laboratory data were obtained, 
which that is, contained glycated hemoglobin (HbA1c), 
total cholesterol, high- density lipoprotein (HDL) choles-
terol and urinary ACR. The eGFR was calculated with the 
Modification of Diet in Renal Disease formula and mean 
arterial pressure (MAP) was defined as (systolic blood 
pressure+2×diastolic blood pressure)/3. Non- HDL was 
calculated by subtracting HDL from total cholesterol. 
To calculate eGFR and ACR percentage change during 
total follow- up, the value at baseline and the last known 
value during follow- up were used. The eGFR and ACR 
percentage change per year were determined by dividing 
the percentage difference during total follow- up by total 
follow- up time in years.
Igg N-glycome analysis
Plasma for IgG N- glycosylation analysis was available 
in 1837 cases, and 22 samples failed quality control, 
resulting in 1815 cases. Isolation, release and labeling of 
IgG glycans has been described in detail previously.5 14 
In total, 24 IgG glycan peaks were measured by Waters 
Acquity UPLC instrument. All chromatograms were sepa-
rated into 24 peaks and the amount of glycans in each 
peak was expressed as percentage of total integrated 
area. From these direct traits, an additional 34 derived 
IgG glycan traits were calculated based on their struc-
tural similarities. As a result, characteristics of the 24 
direct glycan peaks are reflected in the derived traits. A 
detailed description can be found in online supplemen-
tary table S1. The distribution of the IgG glycan peaks was 
analyzed by visual inspection of QQ plots and showed no 
major deviations from normality. IgG glycan expressions 
were globally normalized and log transformed, and all 
measurements were adjusted for batch effects by applying 
ComBat (R- package sva). Before statistical analyses were 
performed, all IgG glycan traits were centered and scaled 
to have mean 0 and SD 1.
glycan nomenclature
A glycan structure formula is described as follows: FAxB-
GxSx. The abbreviations stand for F=fucose, A=antennae, 
B=bisection, G=galactose and S=sialic acid, and x indicates 
the number of the particular feature. When, for example, 
F or S is not present in the structure formula, the glycan 
has no fucose or sialic acids attached. For some glycans, 
for example, GP9 with structure formula FA2[3]G1, [3] 
means the antennae (A2) are bound on the third carbon 
bond of mannose of the glycan core.
statistical analysis
Mean and SD of cohort characteristics were determined. 
Linear regression models were used to investigate asso-
ciations between the 58 IgG glycan patterns and eGFR 
and ACR. Four dependent variables were constructed: 
percentage change of eGFR during total follow- up, 
percentage change ACR during total follow- up, eGFR 
percentage change per year and ACR percentage change 
per year. The basic model for each dependent variable 
included age and sex and their interaction. Different full 
models were constructed, for adjusting for confounders. 
These full models always contained smoking, MAP, body 
mass index (BMI), HbA1c, duration of type 2 diabetes, 
non- HDL and HDL. In addition, in the full models of 
dependent variables eGFR and ACR percentage change 
during total follow- up, we adjusted for duration of 
follow- up. Furthermore, we additionally adjusted the 
full models of the ACR analyses for ACE- inhibitor use. 
We had 80% power to detect Cohen’s effect size f2: 0.009 
based on 1815 cases and 11 predictors.21 Correction for 
multiple comparisons was performed by the Benjamini- 
Hochberg method.22 Statistical analyses were carried out 
using IBM SPSS Statistics V.25.0.
ResulTs
Cohort characteristics
Characteristics of the study population are shown in 
table 1. All participants were aged between 27 and 94 
with a mean of 65.2 years; 53.6% were male, mean BMI 
was 30.5 kg/m2, mean HbA1c was 7.0% and mean dura-
tion of type 2 diabetes at inclusion was 10.1 years. On 
average, the eGFR and ACR percentage change per year 
were −2.3% and 162.2%, respectively. Microalbuminuria 
was present in 2.8% of all patients at baseline and in 5.5% 
at end of follow- up. Macroalbuminuria was present in 
0.2% of the patients at both instances.
Igg glycan associations with egFR percentage change per 
year
In table 2, significant associations between IgG N- glycans 
and eGFR percentage change per year are shown for 
both models. Results for all 58 investigated IgG glycan 
peaks and derived traits are shown in online supplemen-
tary table S2.
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Table 1 Characteristics of the study population
Characteristic Cases (n=1886)
Age (years) 65.2 (±10.6)
Sex (% male) 53.6
BMI (kg/m2) 30.5 (±5.4)
HDL cholesterol (mmol/L) 1.17 (±0.32)
Non- HDL cholesterol (mmol/L) 3.12 (±0.90)
Never smoked (%) 23.3
Former smoker (%) 50.7
Current smoker (%) 16.2
MAP (mm Hg) 98.9 (±10.8)
HbA1c (%) 7.0 (±1.1)
HbA1c (mmol/L) 53.31 (11.58)
Duration type 2 diabetes at inclusion 
(years)
10.1 (±8.4)
Duration of follow- up (years) 6.9 (±2.1)
eGFR change during total follow- up (%) −7.7 (±24.5)
eGFR change per year (%) −2.3 (±24.9)
ACR change during total follow- up (%) 800.5 (±3626.8)
ACR change per year (%) 162.2 (±678.5)
Normoalbuminuria (ACR <30 mg/g) (%) 90.5
Microalbuminuria (ACR 30–300 mg/g) (%) 2.8
Macroalbuminuria (ACR >300 mg/g) (%) 0.2
Normoalbuminuria at follow- up (%) 79.2
Microalbuminuria at follow- up (%) 5.5
Macroalbuminuria at follow- up (%) 0.2
Unless stated otherwise, mean (±SD) are given.
ACR, albumin- to- creatinine ratio; BMI, body mass index; eGFR, 
estimated glomerular filtration rate; HDL, high- density lipoprotein; 
MAP, mean arterial pressure.
In the full model, 1 IgG N- glycan peak and 10 derived 
traits were significantly associated with eGFR percentage 
change per year. Agalactosylated fucosylated biantennary 
glycans with bisecting GlcNAc (GP6; FA2B) were associ-
ated with a faster decrease of eGFR. In addition, bisecting 
GlcNAc in fucosylated disialylated structures (FBS2/
FS2 and FBS2/(FS2+FBS2)), fucosylated structures with 
bisecting GlcNAc (FBn, FBG1n/G1n, FBG2n/G2n, FBn/
Fn and FBn/Fntotal) and the percentage of monosialyla-
tion of all fucosylated digalactosylated structures without 
bisecting GlcNAc (FG2S1/(FG2+FG2S1+FG2S2)) were 
also associated with a faster decrease of eGFR.
Traits associated with less eGFR decline per year were 
fucosylated structures without bisecting GlcNAc in 
neutral (Fn) and monogalactosylated structures (FG1n/
G1n).
Igg glycan associations with egFR percentage change during 
total follow-up
Associations between all 58 investigated IgG glycan 
patterns and the eGFR percentage change during total 
follow- up are shown in online supplementary table S3.
In the basic model, five IgG N- glycan peaks and three 
derived traits were significantly associated with eGFR 
percentage change during total follow- up. However, 
after the adjustment for clinical risk factors, no associa-
tions remained significant. In the basic model, patterns 
associated with a larger decrease in eGFR over time were 
fucosylated biantennary glycans with (GP6: FA2B) and 
without bisecting GlcNAc (GP4: FA2) and agalactosylated 
structures (G0n). Monogalactosylated (GP8: A2BG1, 
FA2[6]G1; GP9: FA2[3]G1), digalactosylated (GP14: 
FA2G2), core fucosylated biantennary glycans without 
bisecting GlcNAc and monogalactosylated (G1n) and 
digalactosylated structures (G2n) were associated with a 
smaller decrease in eGFR over time.
 
Igg glycan associations with aCR
In both models, we did not find any significant association 
between IgG glycan patterns and both ACR percentage 
change and ACR percentage change per year. Associa-
tions between all 58 investigated IgG glycan patterns and 
the ACR percentage change during total follow- up and 
per year are shown in online supplementary table S4 and 
S5, respectively.
dIsCussIon
In the present study, we describe the prospective asso-
ciation of IgG N- glycome with the prospective course 
of kidney function in type 2 diabetes. After adjustment 
for confounders, monosialylation, bisecting GlcNAc and 
fucosylation with bisecting GlcNAc were associated with a 
faster decrease of eGFR per year. Bisecting GlcNAc and 
fucosylated bisected IgG reflect biological aging as well as 
a pro- inflammatory state of IgG. In contrast, fucosylation 
without bisecting GlcNAc was associated with less eGFR 
decline per year. These non- bisected fucosylated IgG can 
implicate an anti- inflammatory IgG effector function. No 
significant associations were found between IgG glycan 
patterns and ACR.
Although the pathogenesis of nephropathy in diabetes 
is only partly understood, it is known that hyperglycemia 
leads to activation of inflammatory pathways, which attri-
butes to the risk of vascular complications due to tissue 
injury.23 24 More specifically, in diabetic nephropathy, 
high blood glucose levels cause renal cells to release 
humoral mediators, pro- inflammatory cytokines and 
growth factors.25 26 Subsequently, GFR deteriorates due to 
changes in kidney structure and function, such as thick-
ening of the glomerular basement membrane and glomer-
ulosclerosis.25–27 Thus, inflammation plays a major role 
in the development of diabetic nephropathy. Changes in 
IgG glycan composition can modify the effector function 
of IgG, hereby contributing to inflammation.28 The role 
of IgG glycans in diabetic nephropathy is supported by an 
in vivo study, in which Fcγ receptor–deficient mice devel-
oped less renal hypertrophy, inflammation and fibrosis.29 
IgG N- glycans change the Fcy receptor affinity, hereby 
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Table 2 Statistically significant associations of IgG glycan traits with eGFR change per year
Glycan traits Basic model Full model
β P value β P value
GP4 (FA2) −1.13 6.17E−03 −0.13 NS
GP6 (FA2B) −1.38 7.76E−04 −0.76 6.18E−03
GP8 (A2BG1; FA2[6]G1) 1.18 2.28E−03 0.61 NS
GP9 (FA2[3]G1) 1.05 5.65E−03 0.44 NS
GP14 (FA2G2) 1.12 1.01E−02 0.49 NS
Derived traits
FG2S1/(FG2+FG2S1+FG2S2) −0.27 NS −0.74 2.66E−03
FBStotal/FStotal −1.16 3.94E−03 −0.31 NS
FBS2/FS2 −1.38 4.16E−04 −0.78 3.20E−03
FBS2/(FS2+FBS2) −1.21 2.25E−03 −0.74 5.89E−03
G0n −1.32 1.84E−03 −0.39 NS
G1n 1.43 3.51E−04 0.34 NS
Fn 0.71 NS 0.70 5.70E−03
FG1n/G1n 0.80 NS 0.71 4.71E−03
FG2n/G2n 1.08 6.09E−03 0.51 NS
FBn −0.73 NS −0.72 4.73E−03
FBG1n/G1n −0.77 NS −0.70 5.24E−03
FBG2n/G2n −1.27 1.42E−03 −0.75 4.11E−03
FBn/Fn −0.77 NS −0.78 2.20E−03
FBn/Fntotal −0.74 NS −0.74 3.89E−03
Basic model: age, sex and their interaction.
Full model: smoking, mean arterial pressure, body mass index, HbA1c, duration of type 2 diabetes, non- HDL, HDL.
A p value was considered statistically significant for the basic model when p<1.01E−02 and for the full model when p<6.18E−03. Regression 
coefficient (beta) and p value per association, with FDRα used as cut- off for significance.
B, bisection; eGFR, estimated glomerular filtration rate; F, fucose; G, galactose; HDL, high- density lipoprotein; N, neutral; NS, non- significant; 
S, sialylation.
regulating inflammatory processes such as antibody- 
dependent cellular phagocytosis and ADCC. IgG glycan 
modulation has also been shown to attenuate the devel-
opment of ANCA- mediated glomerulonephritis.30 IgG 
N- glycosylation patterns have already been associated 
with kidney function in non- diabetic individuals and 
type 1 diabetes.8 9 Key properties of IgG glycosylation are 
galactosylation, sialylation, fucosylation and bisecting 
GlcNAc. We will discuss our findings and associated liter-
ature accordingly.
Galactosylation of IgG N- glycans is essential for the initi-
ation of the anti- inflammatory signaling cascade through 
the inhibitory receptor FcγRIIB.31 In addition, the pro- 
inflammatory activity of the complement component 
C5a can be inhibited by highly galactosylated immune 
complexes.28 32 33 Therefore, galactosylation reflects an 
anti- inflammatory state of IgG. A lack of galactosylation 
is known to activate the complement system via the lectin 
pathway by binding to mannose- binding lectin and via 
the alternative pathway,28 32 34–36 which induces inflamma-
tion. In our study, agalactosylated structures were asso-
ciated with a faster decline of kidney function, whereas 
monogalactosylated structures and GP14 (FA2G2) were 
associated with less kidney function decline per year in 
the basic model. When adjusting for clinical covariates, 
such as HbA1c, these associations did not remain signif-
icant. However, in the extensive model, GP6 (FA2B), of 
which the absence of galactose is an important feature, 
was significantly associated with a faster decline of kidney 
function independent of clinical covariates. These find-
ings are in line with other studies, as agalactosylated IgG 
glycan structures were also associated with a more rapid 
eGFR decline in type 1 diabetes and a higher risk of CKD 
in the non- diabetic population.8 9
In previous studies, the sialylation of IgG glycans 
decreased the affinity of Fcγ receptors, leading to anti- 
inflammatory activity18 37: the addition of sialic acid alters 
IgG from a pro- inflammatory to an anti- inflammatory 
state. In our study, GP6 (FA2B), characterized by 
the absence of sialic acid, was associated with faster 
decrease in kidney function. In line with our finding, 
the percentage of sialylated structures in IgG glycans 
was also decreased in non- diabetic patients with CKD.9 
In our study, a faster decrease in kidney function was 
also associated with monosialylation of fucosylated diga-
lactosylated structures without bisecting GlcNAc, which 
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we cannot completely explain. It could be a result of a 
relative increase, as a consequence of a (non- significant) 
reduction in disialylated structures of the same type. This 
is supported by the overall negative direction of associa-
tion of the percentage of sialylation in these structures.
High abundance of IgG core fucose serves as a “safety 
switch”, as it decreases the affinity for the FcγRIIIA and 
FcγRIIIB receptors.38–40 As a result, core fucose prevents 
ADCC.38–40 However, the presence of bisecting GlcNac 
in fucosylated structures has the opposite effect, as 
it increases the affinity for the receptors mentioned 
above.41 42 The combination of fucose with bisecting 
GlcNac is associated with a pro- inflammatory state of 
IgG. In our study, fucosylated structures with bisecting 
GlcNAc were associated with a faster decrease of kidney 
function after adjustment for clinical variables. This was 
also reflected in the association with GP6 (FA2B), which 
entails the same feature. Moreover, fucosylated structures 
without bisecting GlcNAc were associated with less annual 
kidney function decline. Similar results were found in a 
non- diabetic population, as sialylated core fucosylated 
glycans with bisecting GlcNac were associated with lower 
eGFR.8 Interestingly, monosialylation with presence of 
bisecting GlcNac was associated with lower eGFR in the 
non- diabetic population,8 whereas in our study, disialyla-
tion in combination with bisecting GlcNAc was associated 
with a faster decrease of eGFR.
In our study, we did not find an association of IgG 
glycosylation with prospective changes in albumin-
uria. Increase of ACR is one of the first clinical signs of 
diabetic nephropathy. However, studies in both types of 
diabetes have also shown that higher albuminuria levels 
do not necessarily result into renal function decline.43–45 
A portion of diabetic patients indeed presents with 
normoalbuminuria in combination with a decline in 
renal function.46 47 It has been shown that these patients 
tend to have a higher age and a more advanced CKD with 
lower eGFR and lower hemoglobin.48 This suggests that, 
for these patients, the kidney function decline may be 
related to macrovascular rather than to microvascular 
disease, as may also be the case in our population of 
older patients with type 2 diabetes. As another study45 has 
shown that intrarenal vascular disease is dependent of 
eGFR, but independent of ACR, the associations between 
IgG glycans and renal function found in our study may 
indicate renal macroangiopathy rather than microvas-
cular glomerulopathy. Associations between IgG glycans 
and ACR were described in type 1 diabetes.9 The large 
portion of both microalbuminuria and macroalbumin-
uria at baseline in this type 1 diabetes population (13.45% 
and 10.27% vs 2.8% and 0.2% in our study, respectively) 
may explain this difference.
Strengths of our study are the use of a large and 
unselected cohort of patients with type 2 diabetes from 
all lines of care with prospective follow- up. A variety of 
clinical features was available to include in our analysis. 
Furthermore, this is the first study addressing the IgG 
N- glycome in relation to kidney disease in type 2 diabetes 
and prospectively. Although we have performed our 
study with great care, some limitations remain. First, IgG 
glycans were measured at baseline. As a result, we have 
not investigated temporal sequence glycan composition 
changes, which could have influenced the kidney func-
tion during follow- up. However, IgG glycans are known to 
be fairly stable unless a major physiological change takes 
place.13 Moreover, for biomarker purposes, a marker that 
predicts well with one measurement, rather than sequen-
tial measurements would be preferred. Second, residual 
confounding due to yet unknown factors affecting both 
the IgG N- glycome and kidney function cannot be 
excluded. However, by adjusting for many clinical factors, 
we have reduced this to a minimum. Third, our study has 
only evaluated the IgG N-glycome, which reflects glycans 
originating from IgG. Glycans present on other plasma 
proteins, as can be measured in the total N-glycome, may 
also associate with the prognosis of kidney function.
To conclude, we found IgG N- glycosylation patterns, 
reflecting a pro- inflammatory state of IgG at baseline, 
associated prospectively with a faster decline of kidney 
function in patients with type 2 diabetes. eGFR, but not 
ACR, was associated with IgG glycans, which suggests 
these associations may represent renal macroangiopathy 
rather than microvascular disease.
Our findings suggest the involvement of the immune 
system in the pathophysiology of diabetic nephropathy 
in type 2 diabetes, representing a novel target for future 
biomarker and therapeutics development. Mendelian 
randomization studies and in- depth in vitro studies could 
provide more insight into the causality of the discov-
ered relationships as well as the pathophysiological 
mechanisms.
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